20 December 2019 - PBAC responds to a minor submission from National Aboriginal Community Controlled Health Organisation.

At its November 2019 meeting, the PBAC recommended the Restricted Benefit listing of prednisolone with phenylephrine (Prednefrin Forte) for severe eye inflammation following cataract surgery for patients who identify as Aboriginal and Torres Strait Islander.  This is the first time the PBAC has recommended a medicine for people who identify as an Aboriginal or Torres Strait Islander.

The PBAC considered a submission for another health care technology for use by Aboriginal or Torres Strait Islanders at the November 2019 meeting. The PBAC recommended the listing of multicomponent meningococcal group B vaccine (Bexsero), on the National Immunisation Program, for the prevention of invasive meningococcal disease caused by N. meningitidis group B strain in Aboriginal and Torres Strait Islander children. No mention of its possible use in children who identify as an Aboriginal or Torres Strait islander.

Read recommendations from the November 2019 PBAC meeting